- Home
- LVLU vs INMB Comparison
LVLU vs INMB Comparison
Compare LVLU & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$10.10
HOLD
Current Price
$1.50
Company Overview
Basic Information| Metric | LVLU | INMB |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 34.3M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LVLU | INMB |
|---|---|---|
| Price | $10.10 | $1.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 11.9K | ★ 229.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $50,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.22 | $1.09 |
| 52 Week High | $32.32 | $11.64 |
Technical Indicators
Market Signals| Indicator | LVLU | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 58.04 |
| Support Level | $3.87 | $1.40 |
| Resistance Level | $12.76 | $1.71 |
| Average True Range (ATR) | 1.03 | 0.09 |
| MACD | 0.26 | 0.01 |
| Stochastic Oscillator | 33.52 | 80.70 |
Price Performance
Historical Comparison LVLU
INMB
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.